Yoshiaki Ohtsu

617 total citations
26 papers, 477 citations indexed

About

Yoshiaki Ohtsu is a scholar working on Molecular Biology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yoshiaki Ohtsu has authored 26 papers receiving a total of 477 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 8 papers in Immunology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yoshiaki Ohtsu's work include Biosimilars and Bioanalytical Methods (8 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Herpesvirus Infections and Treatments (4 papers). Yoshiaki Ohtsu is often cited by papers focused on Biosimilars and Bioanalytical Methods (8 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Herpesvirus Infections and Treatments (4 papers). Yoshiaki Ohtsu collaborates with scholars based in Japan, United States and Netherlands. Yoshiaki Ohtsu's co-authors include Jacqueline A. Gibbons, Jan‐Stefan van der Walt, Taoufik Ouatas, Michiel S. de Vries, Joyce Mordenti, Walter Krauwinkel, Roelof Mol, Maria Francesca Riccio, Clark Williard and Kelly Dong and has published in prestigious journals such as SHILAP Revista de lepidopterología, Antimicrobial Agents and Chemotherapy and Biochimica et Biophysica Acta (BBA) - Biomembranes.

In The Last Decade

Yoshiaki Ohtsu

23 papers receiving 460 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yoshiaki Ohtsu Japan 10 184 99 87 82 74 26 477
Mindy Magee United States 14 77 0.4× 124 1.3× 51 0.6× 119 1.5× 47 0.6× 41 567
Hans Stieltjes Belgium 17 132 0.7× 169 1.7× 154 1.8× 247 3.0× 54 0.7× 26 628
Elena Guerini Switzerland 15 222 1.2× 191 1.9× 208 2.4× 37 0.5× 37 0.5× 29 793
Robert Bahnson United States 12 209 1.1× 153 1.5× 119 1.4× 52 0.6× 34 0.5× 25 823
Zhiying Luo China 16 64 0.3× 236 2.4× 149 1.7× 138 1.7× 25 0.3× 40 717
Sarah J. Schrieber United States 11 263 1.4× 156 1.6× 99 1.1× 28 0.3× 43 0.6× 25 606
Adam W. Grasso United States 5 190 1.0× 261 2.6× 119 1.4× 249 3.0× 138 1.9× 6 883
Daria Stypinski United States 14 40 0.2× 81 0.8× 169 1.9× 45 0.5× 97 1.3× 30 562
Ian Holmes United States 13 138 0.8× 162 1.6× 80 0.9× 50 0.6× 10 0.1× 34 609
Matthew Hruska United States 11 64 0.3× 117 1.2× 255 2.9× 33 0.4× 37 0.5× 26 610

Countries citing papers authored by Yoshiaki Ohtsu

Since Specialization
Citations

This map shows the geographic impact of Yoshiaki Ohtsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshiaki Ohtsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshiaki Ohtsu more than expected).

Fields of papers citing papers by Yoshiaki Ohtsu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshiaki Ohtsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshiaki Ohtsu. The network helps show where Yoshiaki Ohtsu may publish in the future.

Co-authorship network of co-authors of Yoshiaki Ohtsu

This figure shows the co-authorship network connecting the top 25 collaborators of Yoshiaki Ohtsu. A scholar is included among the top collaborators of Yoshiaki Ohtsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshiaki Ohtsu. Yoshiaki Ohtsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sun, Yuchen, Takahiro Nakamura, Yoshiaki Ohtsu, et al.. (2023). Development and Validation of qPCR Methods for Nucleic Acid Biomarkers as a Drug Development Tool: Points to Consider. Bioanalysis. 15(17). 1069–1081.
2.
Ohtsu, Yoshiaki, et al.. (2018). Absorption, Distribution, Metabolism, and Excretion of the Novel Helicase-Primase Inhibitor, Amenamevir (ASP2151), in Rodents. European Journal of Drug Metabolism and Pharmacokinetics. 43(6). 693–706. 19 indexed citations
3.
Kato, Kota, et al.. (2018). An Open‐Label, Single‐Dose, Human Mass Balance Study of Amenamevir in Healthy Male Adults. Clinical Pharmacology in Drug Development. 8(5). 595–602. 4 indexed citations
4.
Keirns, James J., et al.. (2017). Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies. Advances in Therapy. 34(12). 2625–2637. 20 indexed citations
5.
Ohtsu, Yoshiaki. (2017). Incurred sample stability of ASP3258 in the presence of its acyl glucuronide. SHILAP Revista de lepidopterología. 3(3). 34–42. 4 indexed citations
6.
García-Hernández, Alberto, et al.. (2017). Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults. Advances in Therapy. 34(11). 2466–2480. 9 indexed citations
7.
Ohtsu, Yoshiaki, et al.. (2017). Quantification of ASP2151 in Human Plasma and Urine: A Pitfall Associated with Supersaturation of Analyte in Urine. Chromatographia. 80(2). 217–227. 7 indexed citations
8.
Hashii, Noritaka, Masahiro Utoh, Yoshiaki Ohtsu, et al.. (2017). Bioanalytical Quantification of Therapeutic Antibodies by Liquid Chromatography/mass Spectrometry. Chromatography. 39(1). 7–19. 1 indexed citations
9.
Ohtsu, Yoshiaki, Jacqueline A. Gibbons, Katsuhiro Suzuki, et al.. (2016). Absorption, Distribution, Metabolism, and Excretion of the Androgen Receptor Inhibitor Enzalutamide in Rats and Dogs. European Journal of Drug Metabolism and Pharmacokinetics. 42(4). 611–626. 9 indexed citations
10.
Gibbons, Jacqueline A., Michiel S. de Vries, Walter Krauwinkel, et al.. (2015). Pharmacokinetic Drug Interaction Studies with Enzalutamide. Clinical Pharmacokinetics. 54(10). 1057–1069. 120 indexed citations
11.
Ohtsu, Yoshiaki, et al.. (2015). Regulated bioanalysis of conformers – A case study with ASP2151 in dog plasma and urine. Journal of Chromatography B. 997. 56–63. 2 indexed citations
12.
13.
Gibbons, Jacqueline A., Taoufik Ouatas, Walter Krauwinkel, et al.. (2015). Clinical Pharmacokinetic Studies of Enzalutamide. Clinical Pharmacokinetics. 54(10). 1043–1055. 109 indexed citations
14.
Merbel, Nico van de, Natasha Savoie, Yoshiaki Ohtsu, et al.. (2014). Stability: Recommendation for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Team. The AAPS Journal. 16(3). 392–399. 52 indexed citations
15.
16.
Ohtsu, Yoshiaki, et al.. (2014). Absorption, distribution, metabolism and excretion of novel phosphodiesterase type 4 inhibitor ASP3258 in rats. Biopharmaceutics & Drug Disposition. 36(1). 34–48. 1 indexed citations
17.
Kobayashi, Miki, Satoshi Kubo, Masahiro Iwata, et al.. (2012). Therapeutic Potential of ASP3258, a Selective Phosphodiesterase 4 Inhibitor, on Chronic Eosinophilic Airway Inflammation. Pharmacology. 90(3-4). 223–232. 9 indexed citations
18.
Katsumata, Kiyomitsu, Koji Chono, Kota Kato, et al.. (2012). Pharmacokinetics and Pharmacodynamics of ASP2151, a Helicase-Primase Inhibitor, in a Murine Model of Herpes Simplex Virus Infection. Antimicrobial Agents and Chemotherapy. 57(3). 1339–1346. 24 indexed citations
19.
Kobayashi, Miki, Satoshi Kubo, Masahiro Iwata, et al.. (2011). ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity. International Immunopharmacology. 11(6). 732–739. 24 indexed citations
20.
Ohtsu, Yoshiaki, K. Tsuchida, Yu Suzuki, & Takayuki Ohnishi. (1982). Effect of concanavalin A on the activity of membrane-bound and detergent-solubilized Mg2+-ATPase. Biochimica et Biophysica Acta (BBA) - Biomembranes. 690(1). 69–73. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mindy Magee Breakdown of academic impact, for papers by Hans Stieltjes Breakdown of academic impact, for papers by Elena Guerini Breakdown of academic impact, for papers by Robert Bahnson Breakdown of academic impact, for papers by Zhiying Luo Breakdown of academic impact, for papers by Sarah J. Schrieber Breakdown of academic impact, for papers by Adam W. Grasso Breakdown of academic impact, for papers by Daria Stypinski Breakdown of academic impact, for papers by Ian Holmes Breakdown of academic impact, for papers by Matthew Hruska
Rankless by CCL
2026